[go: up one dir, main page]

MA38865A1 - Formulation comprenant un agent hypolipidémiant - Google Patents

Formulation comprenant un agent hypolipidémiant

Info

Publication number
MA38865A1
MA38865A1 MA38865A MA38865A MA38865A1 MA 38865 A1 MA38865 A1 MA 38865A1 MA 38865 A MA38865 A MA 38865A MA 38865 A MA38865 A MA 38865A MA 38865 A1 MA38865 A1 MA 38865A1
Authority
MA
Morocco
Prior art keywords
formula
formulation
lowering agent
lipid
compounds
Prior art date
Application number
MA38865A
Other languages
English (en)
Inventor
Jitendre D Patel
Prakash Davadra
Snehal Patel
Shafiq Sheikh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA38865A1 publication Critical patent/MA38865A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique stable d'un agent hypolipidémiant approprié. De préférence, la présente invention décrit de nouvelles formulations du composé de formule (i), ou des sels pharmaceutiquement acceptables de composés de formule (1). Plus particulièrement, la présente invention concerne la composition pharmaceutique stable de composés de formule (i), comprenant des composés de formule (i) ou ses sels pharmaceutiquement acceptables, le ph de la formulation étant maintenu au-dessus de 7. Formule (i)
MA38865A 2013-07-25 2014-07-24 Formulation comprenant un agent hypolipidémiant MA38865A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (fr) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (fr) 2013-07-25 2014-07-24 Formulation comprenant un agent hypolipidémiant

Publications (1)

Publication Number Publication Date
MA38865A1 true MA38865A1 (fr) 2017-12-29

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38865A MA38865A1 (fr) 2013-07-25 2014-07-24 Formulation comprenant un agent hypolipidémiant

Country Status (22)

Country Link
US (2) US9610277B2 (fr)
EP (1) EP3024446A1 (fr)
JP (1) JP2016523895A (fr)
KR (1) KR101786843B1 (fr)
CN (1) CN105407873A (fr)
AP (1) AP2015008876A0 (fr)
AR (1) AR097067A1 (fr)
AU (1) AU2014294548B2 (fr)
BR (1) BR112015031878A2 (fr)
CA (1) CA2917923A1 (fr)
EA (1) EA201690072A1 (fr)
GE (1) GEP20186825B (fr)
HK (1) HK1219222A1 (fr)
IN (1) IN2013MU02470A (fr)
MA (1) MA38865A1 (fr)
MX (1) MX374628B (fr)
NZ (1) NZ714558A (fr)
PH (1) PH12015502802A1 (fr)
SG (1) SG11201509798PA (fr)
TW (1) TW201545773A (fr)
WO (1) WO2015011730A1 (fr)
ZA (1) ZA201508682B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022187B1 (fr) 2006-05-23 2011-03-16 Intel Corporation Système de communication par ondes millimétriques pour zone interieur
DK2670486T3 (en) 2011-01-31 2016-05-17 Cadila Healthcare Ltd TREATMENT FOR LIPODYSTROPHY
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (fr) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (fr) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
EP3551180B1 (fr) 2016-12-09 2021-09-29 Cadila Healthcare Limited Traitement de la cholangite biliaire primitive
WO2020165782A1 (fr) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Traitement du syndrome des ovaires polykystiques (pcos)
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (fr) 1992-07-03 1994-01-20 Smithkline Beecham Plc Composes heterocycliques comme produits pharmaceutiques
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (fr) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxoazoles et derives de pryridine destines a etre utilises pour le traitement du diabete tardif
DE69615016T2 (de) 1995-04-28 2002-05-02 Daiichi Pharmaceutical Co., Ltd. Pentacyclische verbindungen
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
WO1999019313A1 (fr) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant
EP1073643B1 (fr) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
EP1123297A1 (fr) 1998-10-21 2001-08-16 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
EP1123292A1 (fr) 1998-10-21 2001-08-16 Novo Nordisk A/S Nouveaux composes, leur preparation et leur utilisation
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
IL150821A0 (en) 2000-01-19 2003-02-12 Cadila Healthcare Ltd Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (fr) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Procede ameliore pour la preparation de derives d'acide 3-aryl-2-hydroxy propanoique
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
WO2007097386A1 (fr) * 2006-02-22 2007-08-30 Eisai R & D Management Co., Ltd. Composition pharmaceutique stabilisee
WO2007122635A2 (fr) 2006-04-26 2007-11-01 Astron Research Limited Formulation à libération à libération contrôlée comprenant des médicaments anti-épilepiques
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
BR112012012815B8 (pt) 2009-11-26 2021-05-25 Genfit uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico
BR112013008985A2 (pt) * 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
DK2670486T3 (en) * 2011-01-31 2016-05-17 Cadila Healthcare Ltd TREATMENT FOR LIPODYSTROPHY
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (fr) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
EP3039011A1 (fr) 2013-08-29 2016-07-06 Cadila Healthcare Limited Forme polymorphe de dérivé du pyrrole et intermédiaire
IN2013MU02905A (fr) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
MX374628B (es) 2025-03-06
PH12015502802A1 (en) 2016-03-14
AR097067A1 (es) 2016-02-17
US9610277B2 (en) 2017-04-04
AP2015008876A0 (en) 2015-11-30
BR112015031878A2 (pt) 2017-07-25
US20170266158A1 (en) 2017-09-21
IN2013MU02470A (fr) 2015-06-26
HK1219222A1 (zh) 2017-03-31
EA201690072A1 (ru) 2016-06-30
EP3024446A1 (fr) 2016-06-01
CA2917923A1 (fr) 2015-01-29
JP2016523895A (ja) 2016-08-12
SG11201509798PA (en) 2016-02-26
KR101786843B1 (ko) 2017-10-18
US10098868B2 (en) 2018-10-16
NZ714558A (en) 2017-02-24
TW201545773A (zh) 2015-12-16
ZA201508682B (en) 2017-03-29
US20160136131A1 (en) 2016-05-19
AU2014294548B2 (en) 2017-08-10
KR20160013150A (ko) 2016-02-03
WO2015011730A1 (fr) 2015-01-29
MX2015016971A (es) 2016-04-25
CN105407873A (zh) 2016-03-16
AU2014294548A1 (en) 2015-12-17
GEP20186825B (en) 2018-02-26

Similar Documents

Publication Publication Date Title
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MA37834A1 (fr) Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201270216A1 (ru) Фармацевтический состав
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA37886A1 (fr) Nouvelles pyridinones bicycliques
EA201892815A1 (ru) Новые антибактериальные соединения
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
MA39983A (fr) Dérivés de carboxamide
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
MX385971B (es) Compuesto de griseofulvina.
UA103329C2 (ru) Соли соединений-ингибиторов вич
MX2009008028A (es) Agentes antiparasitarios.
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
MA39305A3 (fr) Dérivés d'éthynyle